Influenza A Virus Matrix Protein 1-Specific Human CD8<sup>+</sup>T-Cell Response Induced in Trivalent Inactivated Vaccine Recipients

Terajima, Masanori; Cruz, John; Leporati, Anita M.; Orphin, Laura; Babon, Jenny Aurielle B.; Co, Mary Dawn T.; Pazoles, Pamela P.; Jameson, Julie; Ennis, Francis A.

doi:10.1128/jvi.01047-08

Cited by 38 publications

(30 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Here we showed that TIV (GlaxoSmithKline) induced HLA-A2/M1 58-66 -tetramer ϩ CD8 ϩ T cells in 20% of HLA-2-positive individuals, as this vaccine contains a relatively high level of M protein (11). Consistent with our finding, recent studies also showed that TIV (Sanofi Pasteur) could induce HLA-A2/M1-tetramer ϩ CD8 ϩ T cells in 12 to 25% of HLA-2-positive individuals (45,51). Live attenuated influenza vaccine (LAIV) is expected to induce T-cell responses more efficiently than TIV, as it contains all the viral internal proteins.…”

Section: Cross-response Of Bulk Ctls Against Pdmh1n1 In Healthy Indivsupporting

confidence: 80%

“…Since there is a very low frequency of influenza virus-specific T cells in human peripheral blood, most studies have used IFN-␥ responses to investigate the cross-reactive T-cell responses or have used influenza virus peptide-pulsed cell lines or cell lines in which HA, NA, and M proteins are expressed as target cells to determine the cross-reactive CTLs of in vitroexpanded CD8 T-cell lines (5,23,29,51). However, these assays have some limitations.…”

Section: Cross-response Of Bulk Ctls Against Pdmh1n1 In Healthy Indivmentioning

confidence: 99%

See 1 more Smart Citation

Cytotoxic T Lymphocytes Established by Seasonal Human Influenza Cross-React against 2009 Pandemic H1N1 Influenza Virus

Mao

Zheng

et al. 2010

J Virol

138

127

View full text Add to dashboard Cite

While few children and young adults have cross-protective antibodies to the pandemic H1N1 2009 (pdmH1N1) virus, the illness remains mild. The biological reasons for these epidemiological observations are unclear. In this study, we demonstrate that the bulk memory cytotoxic T lymphocytes (CTLs) established by seasonal influenza viruses from healthy individuals who have not been exposed to pdmH1N1 can directly lyse pdmH1N1-infected target cells and produce gamma interferon (IFN-␥) and tumor necrosis factor alpha (TNF-␣). Using influenza A virus matrix protein 1 (M1 58-66 ) epitope-specific CTLs isolated from healthy HLA-A2 ؉ individuals, we further found that M1 58-66 epitope-specific CTLs efficiently killed both M1 58-66 peptide-pulsed and pdmH1N1-infected target cells ex vivo. These M1 58-66 -specific CTLs showed an effector memory phenotype and expressed CXCR3 and CCR5 chemokine receptors. Of 94 influenza A virus CD8 T-cell epitopes obtained from the Immune Epitope Database (IEDB), 17 epitopes are conserved in pdmH1N1, and more than half of these conserved epitopes are derived from M1 protein. In addition, 65% (11/17) of these epitopes were 100% conserved in seasonal influenza vaccine H1N1 strains during the last 20 years. Importantly, seasonal influenza vaccination could expand the functional M1 58-66 epitope-specific CTLs in 20% (4/20) of HLA-A2 ؉ individuals. Our results indicated that memory CTLs established by seasonal influenza A viruses or vaccines had cross-reactivity against pdmH1N1. These might explain, at least in part, the unexpected mild pdmH1N1 illness in the community and also might provide some valuable insights for the future design of broadly protective vaccines to prevent influenza, especially pandemic influenza.

show abstract

Section: Cross-response Of Bulk Ctls Against Pdmh1n1 In Healthy Indivsupporting

confidence: 80%

Section: Cross-response Of Bulk Ctls Against Pdmh1n1 In Healthy Indivmentioning

confidence: 99%

Cytotoxic T Lymphocytes Established by Seasonal Human Influenza Cross-React against 2009 Pandemic H1N1 Influenza Virus

Mao

Zheng

et al. 2010

J Virol

138

127

View full text Add to dashboard Cite

show abstract

“…Although only 31% of the B-cell epitopes were conserved, 41% of the CD4 ϩ and 69% of the CD8 ϩ T-cell epitopes were conserved. It is known that crossreactive T-cell immune responses can exist even between serologically distinct influenza A strains (14,15). Based on this observation and the data presented above, we hypothesized that it is possible that immune memory responses against S-OIV exist in the adult population, at the level of both B and T cells.…”

Section: Discussionmentioning

confidence: 83%

Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population

Greenbaum

Kotturi²,

Kim³

et al. 2009

Proc. Natl. Acad. Sci. U.S.A.

295

297

View full text Add to dashboard Cite

A major concern about the ongoing swine-origin H1N1 influenza virus (S-OIV) outbreak is that the virus may be so different from seasonal H1N1 that little immune protection exists in the human population. In this study, we examined the molecular basis for pre-existing immunity against S-OIV, namely the recognition of viral immune epitopes by T cells or B cells/antibodies that have been previously primed by circulating influenza strains. Using data from the Immune Epitope Database, we found that only 31% (8/26) of B-cell epitopes present in recently circulating H1N1 strains are conserved in the S-OIV, with only 17% (1/6) conserved in the hemagglutinin (HA) and neuraminidase (NA) surface proteins. In contrast, 69% (54/78) of the epitopes recognized by CD8 ؉ T cells are completely invariant. We further demonstrate experimentally that some memory T-cell immunity against S-OIV is present in the adult population and that such memory is of similar magnitude as the pre-existing memory against seasonal H1N1 influenza. Because protection from infection is antibody mediated, a new vaccine based on the specific S-OIV HA and NA proteins is likely to be required to prevent infection. However, T cells are known to blunt disease severity. Therefore, the conservation of a large fraction of T-cell epitopes suggests that the severity of an S-OIV infection, as far as it is determined by susceptibility of the virus to immune attack, would not differ much from that of seasonal flu. These results are consistent with reports about disease incidence, severity, and mortality rates associated with human S-OIV.databases ͉ epitopes ͉ meta-analysis ͉ pandemic

show abstract

“…This might be explained by that the ELISA measures IgG against epitopes from the hemagglutinin, the neuraminidase and trace amounts of the matrix 1 protein. [28][29][30][31] Apart from the neutralization epitopes of HA, these other epitopes may be beneficial in Ab-dependent cell-mediated cytotoxicity and complement fixation.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study

Ambati

Boas

Ljungman

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

Pretransplant influenza vaccination of the donor or allogeneic hematopoietic SCT (HSCT) candidate was evaluated in a randomized study. One hundred and twenty-two HSCT recipients and their donors were assigned to three randomization groups: no pretransplant vaccination (n = 38), donor pretransplant vaccination (n = 44) or recipient pretransplant vaccination (n = 40). Specific IgG was assessed by both hemagglutinin inhibition (HI) and, in 57 patients, by an indirect influenza-specific ELISA at specified times after HSCT. Vaccinated donors had seroprotective HI titers for Ags H1 and H3 (Po 0.001) compared with the other groups at the time of donation. The titers against H1 (P = 0.028) and H3 (P o 0.001) were highest in the pretransplant recipient vaccination group until day 180 after transplantation. A significant difference was found in the specific Ig levels against pandemic H1N1 at 6 months after SCT (P = 0.02). The mean IgG levels against pandemic H1N1 and generic H1N1 and H3N2 were highest in the pretransplant recipient vaccination group. We conclude that pretransplant recipient vaccination improved the influenza-specific seroprotection rates.

show abstract

Influenza A Virus Matrix Protein 1-Specific Human CD8⁺T-Cell Response Induced in Trivalent Inactivated Vaccine Recipients

Cited by 38 publications

References 29 publications

Cytotoxic T Lymphocytes Established by Seasonal Human Influenza Cross-React against 2009 Pandemic H1N1 Influenza Virus

Cytotoxic T Lymphocytes Established by Seasonal Human Influenza Cross-React against 2009 Pandemic H1N1 Influenza Virus

Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population

Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study

Contact Info

Product

Resources

About

Influenza A Virus Matrix Protein 1-Specific Human CD8+T-Cell Response Induced in Trivalent Inactivated Vaccine Recipients

Cited by 38 publications

References 29 publications

Cytotoxic T Lymphocytes Established by Seasonal Human Influenza Cross-React against 2009 Pandemic H1N1 Influenza Virus

Cytotoxic T Lymphocytes Established by Seasonal Human Influenza Cross-React against 2009 Pandemic H1N1 Influenza Virus

Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population

Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study

Contact Info

Product

Resources

About

Influenza A Virus Matrix Protein 1-Specific Human CD8⁺T-Cell Response Induced in Trivalent Inactivated Vaccine Recipients